SANUWAVE Health reported record preliminary revenues for Q4 2025 and full-year 2025, with significant year-over-year growth. The company disclosed a restatement related to historical tax liabilities and secured new financing facilities to support operations.

• SANUWAVE Health announced preliminary Q4 2025 revenue of $13.3 to $13.4 million, up 29–30% year-over-year, achieving record quarterly and full-year revenue [N3][N2].
• The company reported record preliminary revenues of $10.1 to $10.2 million for Q2 2025, marking a 41% increase year-over-year [N15].
• SANUWAVE Health beat Q3 earnings and revenue expectations as reported in November 2025 [N4].
• Management disclosed a restatement of prior financial periods due to historical state sales and use tax liabilities, with increases in liabilities and expenses expected [S7][S8].
• SANUWAVE entered into a $23 million secured term loan and a $5 million revolving credit facility in September 2025 to support working capital and repay prior indebtedness [S13].
• The company faces risks related to information technology systems, including cybersecurity breaches and data leakage [S1][S5].

SANUWAVE Health has shown consistent revenue growth with record quarterly and full-year revenues in 2025, supported by new financing arrangements. The company’s ability to manage historical tax liabilities and maintain liquidity ratios above 1.0 suggests operational resilience. Continued execution on commercial operations and market expansion could enhance business stability and growth potential.

The company faces risks from restatements related to historical tax liabilities, which may affect financial reporting and internal controls. Dependence on information technology systems exposes SANUWAVE to cybersecurity and data leakage risks. Limited disclosure on product pipeline, market share, and competitive landscape creates uncertainty about long-term business sustainability and profitability.

SANUWAVE Health operates in a specialized healthcare segment with proprietary technology and products that have demonstrated revenue growth and market acceptance. The company’s ability to achieve record revenues and secure financing indicates operational progress. However, the absence of detailed industry classification and limited public disclosure on competitive positioning and intellectual property limits clarity on sustainable competitive advantages.

• Financial Restatement Risk: SANUWAVE identified historical state sales and use tax liabilities requiring restatement of prior financial periods, increasing reported liabilities and expenses, which may affect investor confidence and financial transparency.
• Information Technology and Cybersecurity Risk: The company depends on IT systems and infrastructure that face risks including cybersecurity breaches and data leakage, potentially impacting operations and data integrity.
• Liquidity and Debt Covenants Risk: SANUWAVE has a secured term loan and revolving credit facility with financial covenants that limit additional indebtedness and require compliance with leverage and coverage ratios, posing risks if financial performance deteriorates.

• SANUWAVE Health, Inc. is a publicly traded company on The Nasdaq Stock Market under the ticker SNWV.
• The company filed its latest annual report (10-K) on March 26, 2026, covering the fiscal year ended December 31, 2025 [S1].
• For the fiscal year ended December 31, 2025, SANUWAVE reported revenue of $44.05 million and net income of $11.813 million [S1].
• Basic earnings per share for 2025 were $1.38, and diluted EPS was $0.41 [S1].
• As of December 31, 2025, the company held $11.959 million in cash and cash equivalents, with current assets of $24.627 million and current liabilities of $17.847 million, resulting in a current ratio of 1.38 and a cash ratio of 0.67 [S1].
• SANUWAVE Health announced preliminary Q4 2025 revenue of $13.3 to $13.4 million, representing a 29–30% year-over-year increase and record quarterly and full-year revenue [N3][N2].
• The company reported record preliminary revenues of $10.1 to $10.2 million for Q2 2025, marking a 41% increase year-over-year [N15].
• SANUWAVE Health beat Q3 earnings and revenue expectations as reported in November 2025 [N4].
• The company entered into a $23 million secured term loan and a $5 million secured revolving credit facility in September 2025, with customary covenants and repayment terms [S13].
• Management identified a historical state sales and use tax liability requiring restatement of prior financial periods, with expected increases in liabilities and expenses disclosed in March 2026 filings [S7][S8].
• The company is dependent on information technology systems and faces risks including cybersecurity breaches and data leakage [S1][S5].